Today: 28 June 2026
Browse Category

NYSE:CYTK 2 January 2026

Cytokinetics (CYTK) stock closes up 3.5% into year-end as Myqorzo launch nears, insider sale disclosed

Cytokinetics (CYTK) stock closes up 3.5% into year-end as Myqorzo launch nears, insider sale disclosed

Cytokinetics shares closed up 3.5% at $63.54, ahead of the planned U.S. launch of Myqorzo for obstructive hypertrophic cardiomyopathy. EVP Andrew Callos sold 1,809 shares at $62.44 under a preset trading plan, retaining 51,353 shares. Investors await U.S. pricing, early prescription data, and a late February earnings update. Myqorzo carries a boxed warning and REMS safety requirements.
2 January 2026
·

Stock Market Today

  • SpaceX Set to Join Nasdaq 100, Potential $4.3 Billion Market Boost for SPCX Stock
    June 28, 2026, 8:05 AM EDT. SpaceX ($SPCX), Elon Musk's aerospace and artificial intelligence firm, will join the Nasdaq 100 index on July 7. Inclusion in this key benchmark, which tracks the largest non-financial companies on the Nasdaq stock exchange, could trigger significant passive buying as index funds adjust holdings. Analysts estimate this shift may inject approximately $4.3 billion of demand into SPCX stock. This move underscores SpaceX's growing market footprint following its direct listing and highlights ongoing investor interest in the aerospace and technology sectors.

Latest articles

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 28.06.2026

28 June 2026
LIVEMarkets rolling coverageStarted: June 28, 2026, 4:00 AM EDTUpdated: June 28, 2026, 8:10 AM EDT SpaceX Set to Join Nasdaq 100, Potential $4.3 Billion Market Boost for SPCX Stock June 28, 2026, 8:05 AM EDT. SpaceX ($SPCX), Elon Musk’s aerospace and artificial intelligence firm, will join the Nasdaq 100 index on July 7. Inclusion in this key benchmark, which tracks the largest non-financial companies on the Nasdaq stock exchange, could trigger significant passive buying as index funds adjust holdings. Analysts estimate this shift may inject approximately $4.3 billion of demand into SPCX stock. This move underscores SpaceX’s growing market footprint
Go toTop